ad

Par Drugs And Chemicals Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

Par Drugs And Chemicals share price Rs 140.92 on 15 September 2026, up 0.00%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 4.71 crore. Q2 FY26 base a profit of Rs 4.13 crore.


15 Sept 2026 • 9:31 am

Par Drugs And Chemicals Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

Quick Answer

The Par Drugs And Chemicals Q2 results date for FY27 is not confirmed, and Par Drugs And Chemicals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 15 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 28.66 crore in revenue and a profit of Rs 4.13 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.

The Par Drugs And Chemicals Q2 results FY27 announcement is the next scheduled earnings event for Par Drugs And Chemicals Ltd., a manufacturer of active pharmaceutical ingredients and fine chemicals. The stock traded at Rs 140.92 on the NSE on 15 September 2026, up 0.00% from the previous close of Rs 140.92, about 21.7% below its 52-week high of Rs 180.00 and 80.6% above its 52-week low of Rs 78.05.

What makes the Par Drugs And Chemicals Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 28.66 crore of revenue and a profit of Rs 4.13 crore, while the most recent quarter on record, Q1 FY27, produced Rs 31.28 crore and a profit of Rs 4.71 crore. Everything below is built from those reported figures rather than from any forecast.

Click Here – Get Free Investment Predictions

When Is the Par Drugs And Chemicals Q2 Results FY27 Date?

The Par Drugs And Chemicals Q2 results date for FY27 is not confirmed. As of 15 September 2026, Par Drugs And Chemicals Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.

What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Par Drugs And Chemicals Q2 results date becomes public through that filing rather than through any advance announcement.

The Par Drugs And Chemicals Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Par Drugs And Chemicals.

Par Drugs And Chemicals Q2 Results Expectations: What the Market Is Actually Tracking

No verified analyst estimate for the Par Drugs And Chemicals Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Par Drugs And Chemicals. The Par Drugs And Chemicals Q2 results watchlist below is built from what the company has actually reported and disclosed.

Par Drugs' standalone revenue has been lumpy rather than smoothly seasonal, at Rs 26.05 crore in June 2025, Rs 28.66 crore in September 2025, Rs 29.34 crore in December 2025, a dip to Rs 19.61 crore in March 2026 and a rebound to Rs 31.28 crore in June 2026. The company's history shows similar swings, such as a 32.9% operating margin quarter followed by one as low as 6.7%, consistent with an order-driven API and fine chemicals business rather than one with predictable quarterly seasonality. This volatility is a factor to keep in mind when comparing the September 2026 quarter to any single prior quarter.

Operating margin held in a healthy 20-21% band in September 2025 (21.14%), December 2025 (20.62%) and June 2026 (20.36%), but dropped sharply to just 7.34% in March 2026, the lowest reading in the recent quarterly series, before recovering. Whether the September 2026 quarter holds near the 20% band seen in three of the last five quarters, or shows renewed compression like March 2026, is one of the clearer operating threads to track.

The March 2026 quarter is a special case: alongside its weak 7.34% operating margin, the company recorded a negative effective tax rate of -3.61%, meaning it booked a net tax credit or write-back rather than a tax expense that quarter. This lifted March 2026 net profit to Rs 0.85 crore even though operating profit was only Rs 1.44 crore, its weakest of the five quarters shown, so that quarter's net profit does not track the operating trend cleanly. Net profit in the other quarters was Rs 3.33 crore (June 2025), Rs 4.13 crore (September 2025), Rs 4.80 crore (December 2025) and Rs 4.71 crore (June 2026); investors comparing the September 2026 print to March 2026 should account for this tax-related distortion rather than reading it as a like-for-like base.

Check Par Drugs And Chemicals Ltd. Live Fundamentals on the Univest Screener

Par Drugs And Chemicals Q2 Results Preview: The Q1 FY27 Actuals It Builds On

Par Drugs And Chemicals Ltd. reported revenue of Rs 31.28 crore in Q1 FY27, up 20.08% from Rs 26.05 crore in Q1 FY26, and a profit of Rs 4.71 crore at the net level, up 41.44% from Rs 3.33 crore in Q1 FY26. These are reported actuals, not estimates.

Sequentially, revenue was up 59.51% over the March 2026 quarter figure of Rs 19.61 crore, and net profit was up 454.12% from Rs 0.85 crore in Q4 FY26. Operating margin stood at 20.36% in Q1 FY27 against 21.14% in the September 2025 quarter, which is the comparison the Par Drugs And Chemicals Q2 results print will be read against.

Q2 FY26 Base: The Comparison Par Drugs And Chemicals Q2 Results FY27 Must Beat

Par Drugs And Chemicals Ltd. reported revenue of Rs 28.66 crore and a profit of Rs 4.13 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Par Drugs And Chemicals Q2 results preview.

Net profit in that base quarter was below the Rs 4.71 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 28.66 crore sits below the Rs 31.28 crore of the June 2026 quarter, which frames how much sequential movement the Par Drugs And Chemicals Q2 results print needs to show growth.

Par Drugs And Chemicals Quarterly Results Trend Over the Last Four Quarters

Quarter Revenue (Rs Cr) Net Profit (Rs Cr)
Q2 FY26 (Sep 2025) 28.66 4.13
Q3 FY26 (Dec 2025) 29.34 4.80
Q4 FY26 (Mar 2026) 19.61 0.85
Q1 FY27 (Jun 2026) 31.28 4.71

Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company's exchange filings, and they are the only basis this Par Drugs And Chemicals Q2 results preview uses.

Revenue across those four quarters ranged from Rs 19.61 crore to Rs 31.28 crore, and net profit from Rs 0.85 crore to Rs 4.80 crore. That spread is the honest context for the Par Drugs And Chemicals Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.

Key Factors That Could Shape Par Drugs And Chemicals Q2 Results FY27

The Par Drugs And Chemicals Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Par Drugs And Chemicals has already reported.

Stock Trades at a Modest Book Multiple

Par Drugs currently trades at a P/E of about 12.0 times and a price-to-book ratio of roughly 1.55 times, at a current market price of Rs 140.92, against a return on equity of 9.95%. These multiples are lower than many small-cap peers in the space and give a factual valuation backdrop, separate from any view on future performance.

Price Sits Well Above Both Moving Averages

The stock's current price of Rs 140.92 is well above its 50-day moving average of Rs 107.56 and its 200-day moving average of Rs 96.22. Its RSI reading of 67.72 is on the higher side of the typical 30-70 range, and the share has traded between a 52-week low of Rs 78.05 and a 52-week high of Rs 180.00.

No Dividends Despite Repeated Profitability

Par Drugs has not paid a dividend in recent years despite reporting a net profit in every one of the last five quarters shown. Five-year sales growth has been modest at roughly 11.3%, a data point worth weighing alongside the quarter-to-quarter revenue and margin swings described above. Anyone tracking the Par Drugs And Chemicals Q2 results release should read these balance-sheet and payout facts alongside the operating trend rather than in isolation.

Par Drugs And Chemicals Q2 Results FY27: Share Price and Valuation Going Into the Print

Par Drugs And Chemicals share price today is Rs 140.92 on the NSE, up Rs 0.00 or 0.00% from the previous close of Rs 140.92 on 15 September 2026, ahead of the Par Drugs And Chemicals Q2 results announcement.

Metric Value (15 September 2026)
NSE Symbol PAR
Current Market Price Rs 140.92
52-Week High Rs 180.00
52-Week Low Rs 78.05
Market Capitalisation Rs 173 crore
PE Ratio 12.00
PB Ratio 1.55
EPS (TTM) Rs 11.74
Book Value per Share Rs 91.00
Debt to Equity 0.00
Return on Equity 9.95%
50-Day Moving Average Rs 107.56
200-Day Moving Average Rs 96.22
RSI (14) 67.72

The stock trades above both its 50-day average of Rs 107.56 and its 200-day average of Rs 96.22, with a 14-day RSI of 67.72. None of this is a view on where the shares go once the Par Drugs And Chemicals Q2 results are announced, and no price target is offered here.

Download the Univest iOS App or Univest Android App to track Par Drugs And Chemicals Ltd. live price and quarterly earnings updates.

What Investors Should Watch When Par Drugs And Chemicals Q2 Results Are Announced

Four lines carry most of the information in a company of this size, and reading them in order keeps the Par Drugs And Chemicals Q2 results print in proportion.

  1. Revenue against the Rs 28.66 crore reported in the September 2025 base quarter
  2. Net profit against a profit of Rs 4.13 crore in that same quarter
  3. Operating margin against 20.36% in Q1 FY27
  4. Any exceptional item, provision or one-off gain disclosed alongside the numbers

A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Par Drugs And Chemicals Q2 results announcement should be read together with the notes to the results rather than the headline alone.

Conclusion on Par Drugs And Chemicals Q2 Results FY27

The Par Drugs And Chemicals Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Par Drugs And Chemicals Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.

On that basis the Par Drugs And Chemicals Q2 results FY27 print faces a base of Rs 28.66 crore in revenue and a profit of Rs 4.13 crore, with the most recent quarter having delivered Rs 31.28 crore and a profit of Rs 4.71 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Par Drugs And Chemicals, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Par Drugs And Chemicals Q2 Results FY27

What is the Par Drugs And Chemicals Q2 results date for FY27?

Ans. The Par Drugs And Chemicals Q2 results date for FY27 is not confirmed. Par Drugs And Chemicals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 15 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.

What quarter do the Par Drugs And Chemicals Q2 results 2026 cover?

Ans. The Par Drugs And Chemicals Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Par Drugs And Chemicals Ltd. reports revenue, operating profit and net profit for that period, and the Par Drugs And Chemicals Q2 results filing also carries the notes to the accounts.

What were the Par Drugs And Chemicals Q1 FY27 results?

Ans. Par Drugs And Chemicals Ltd. reported revenue of Rs 31.28 crore in Q1 FY27 and a profit of Rs 4.71 crore at the net level. Revenue was up 20.08% versus Q1 FY26 and net profit was up 41.44% from Rs 3.33 crore in Q1 FY26.

What were Par Drugs And Chemicals Q2 FY26 results in the September 2025 quarter?

Ans. Par Drugs And Chemicals Ltd. reported revenue of Rs 28.66 crore and a profit of Rs 4.13 crore in Q2 FY26. Operating margin was 21.14%. Those figures form the base for the Par Drugs And Chemicals Q2 results FY27 comparison.

What are the main Par Drugs And Chemicals Q2 results expectations this quarter?

Ans. No verified analyst estimate is publicly available. The Par Drugs And Chemicals Q2 results expectations centre on revenue against the Rs 28.66 crore base, net profit against a profit of Rs 4.13 crore, operating margin against 20.36% in Q1 FY27, and any exceptional item disclosed with the numbers.

What is Par Drugs And Chemicals share price today ahead of the Q2 earnings?

Ans. Par Drugs And Chemicals share price is Rs 140.92 on the NSE as of 15 September 2026, up 0.00% from Rs 140.92. The stock is about 21.7% below its 52-week high of Rs 180.00 and 80.6% above its 52-week low of Rs 78.05, at a market capitalisation of Rs 173 crore.

Is Par Drugs And Chemicals a good stock to buy before the Q2 results?

Ans. This article does not offer a buy, sell or hold recommendation on Par Drugs And Chemicals Ltd. The stock trades at a price-to-book ratio of 1.55 with a return on equity of 9.95%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down